BioSpace News Archive

Beyond Cancer, Ltd., an affiliate of Beyond Air, Inc. (NASDAQ: XAIR) that is developing ultra-high concentration nitric oxide (UNO) as an immunotherapeutic for solid tumors, today announced encouraging first-in-human and first-in-class clinical data demonstrating a promising safety profile and clear evidence of immune system activation via biomarker response.

Cidara Therapeutics, Inc. (Nasdaq: CDTX), today announced new preclinical data on its drug-Fc conjugate (DFC) candidate, CBO421, at the Society for Immunotherapy of Cancer (SITC)’s 38th Annual Meeting.

MiNK Therapeutics, Inc. (NASDAQ: INKT) today presented new agenT-797 data in solid tumor cancers at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting.

Immutep Limited announces new biomarker data from the TACTI-002/KEYNOTE-798 Phase II trial evaluating eftilagimod alpha, a soluble LAG-3 protein and first-in-class MHC Class II agonist administered subcutaneously, in combination with MSD’s anti-PD-1 therapy KEYTRUDA® as first-line treatment for patients with previously untreated unresectable or metastatic non-small cell lung cancer.

Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL) today announced initial positive interim survival and immunological biomarker data from the ongoing randomized phase 2 clinical trial of CAN-2409 plus valacyclovir (prodrug) together with standard of care (SoC) chemoradiation followed by resection for borderline resectable pancreatic ductal adenocarcinoma (PDAC).

Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today presented new data on its masked, anti-CTLA-4 SAFEbody ADG126 at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting taking place in San Diego.

Xilio Therapeutics, Inc. (Nasdaq: XLO) today announced initial safety, pharmacokinetic (PK), pharmacodynamic (PD) and anti-tumor activity data from its ongoing Phase 1/2 clinical trial evaluating XTX202, an investigational tumor-activated, engineered, beta-gamma IL-2, in late line patients with advanced solid tumors.

Alkeus Pharmaceuticals today announced positive data from its TEASE-1 study, a randomized, double-masked, placebo-controlled clinical trial investigating the effects of gildeuretinol (ALK-001) in patients with Stargardt disease.

Immunitas Therapeutics (“Immunitas”) today presented the first proof-of-concept data on its second program, a myeloid and B cell modulating anti CLEC2D-Toll-like receptor 9 (TLR9) agonist conjugate, at the Society for Immunotherapy of Cancer’s 38th Annual Meeting (SITC 2023), held November 1-5 in San Diego, California.

NKILT Therapeutics, Inc., a preclinical-stage cell therapy biotech company developing proprietary Chimeric ILT-Receptor (CIR™)–engineered natural killer (NK) cell therapies, announced today that preclinical data of the CIR™NK cells have been selected for an oral presentation at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition, being held December 9-12, 2023.